Reflections on the dynamic ISSCR 2024 workshop on Standards for Human Stem Cell Use in Research including recommendations for growth factor supply chains for raw (ancillary materials) for cell therapy and ATMP manufacture.
Commercial sources of recombinant human GDF15 protein, in particular those purified from mammalian expression, are frequently contaminated with trace amounts of TGFβ and related proteins. These trace contaminants cause misleading experimental results due to the picomolar or even femtomolar EC50s of this family of cytokines. Please be cautious with your source of recombinant GDF15 protein.
Specialist bioactive growth factor protein manufacturer Qkine today announced a new partnership with StemCultures, a life sciences company dedicated to developing innovative reagents that enhance the quality and efficiency of cell growth and differentiation in culture.
The manufacture of cell and gene therapy products and tissue-engineered regenerative medicine products often requires recombinant proteins such as growth factors and cytokines. These are classified as raw or ancillary materials ie. culture media components or reagents that are not intended to be included in the final product.
In this edition, we are excited to announce our complete transition to animal origin-free (AOF) manufacturing for all recombinant proteins. This ensures the highest quality and consistency for researchers relying on these critical components. Additionally, discover our latest application notes featuring AOF BDNF and GDNF for neural differentiation and thermostable FGF-2 and TGF-β1 for weekend-free iPSC culture.
We've recently fully transitioned to an animal origin-free (AOF) manufacturing process for our recombinant proteins. This shift ensures the highest standards of safety, purity, and sustainability in bioproduction. By eliminating all animal-derived components, including heparin-based purification columns, we’re supporting ethical and cruelty-free biomanufacturing. Learn more about our journey to 100% AOF.
In this edition, explore our latest data on TGF-beta family proteins designed to facilitate faster optimization of cell culture media. Additionally, you will find other resources to support your research, learn about our upcoming events, and much more.
Welcome to our first newsletter of the year, where we will be highlighting new additions to our portfolio, resources to help your research, our latest promotional offer and upcoming event.
Organoids are exciting models that are rapidly becoming a hopeful platform for many medical advances such as drug screening and disease modeling. However, due to a lack of vascularization, they have limitations for future applications. This review blog summarizes several practical methods for successful organoid vascularization to date.
This edition highlights some of our latest resources and products. These include our high-purity mouse/rat Noggin, our newly launched Flt3L (Qk087) to our growing hematopoietic stem cell range and our latest blog on liver organoids emerging as a transformative model for malaria drug discovery.
© 2024 Qkine Ltd. Company number 10470662 registered in England and Wales. All rights reserved
